

Philipp Wolf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/851473/publications.pdf>

Version: 2024-02-01

42
papers

1,685
citations

361413

20
h-index

289244

40
g-index

43
all docs

43
docs citations

43
times ranked

2746
citing authors

#	ARTICLE	IF	CITATIONS
1	The potential of CAR T cell therapy for prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 556-571.	3.8	25
2	Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer. <i>Anticancer Research</i> , 2021, 41, 3741-3746.	1.1	4
3	Targeted Toxins for the Treatment of Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 986.	3.2	5
4	Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer. <i>Toxins</i> , 2020, 12, 753.	3.4	11
5	PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 226-235.	4.4	25
6	An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells. <i>Cancers</i> , 2020, 12, 1648.	3.7	10
7	Tumor-Specific Induction of the Intrinsic Apoptotic Pathway – A New Therapeutic Option for Advanced Prostate Cancer?. <i>Frontiers in Oncology</i> , 2019, 9, 590.	2.8	9
8	Impact of Green Tea Catechin ECG and Its Synthesized Fluorinated Analogue on Prostate Cancer Cells and Stimulated Immunocompetent Cells. <i>Planta Medica</i> , 2018, 84, 813-819.	1.3	20
9	When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. <i>MAbs</i> , 2018, 10, 539-546.	5.2	74
10	Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 413-422.	4.2	11
11	In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 61-69.	1.1	10
12	Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells. <i>Anticancer Research</i> , 2018, 38, 1369-1375.	1.1	9
13	Enterolactone glucuronide and β -glucuronidase in antibody directed enzyme prodrug therapy for targeted prostate cancer cell treatment. <i>AAPS PharmSciTech</i> , 2017, 18, 2336-2345.	3.3	16
14	BH3 Mimetics for the Treatment of Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 557.	3.5	13
15	Methadone as a "Tumor Therapeutic" against Cancer. <i>Frontiers in Pharmacology</i> , 2017, 8, 733.	3.5	13
16	Treatment of metastatic prostate cancer after STAMPEDE. <i>Translational Andrology and Urology</i> , 2017, 6, 315-316.	1.4	3
17	Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry. <i>Oncotarget</i> , 2016, 7, 8839-8849.	1.8	80
18	<i>In vitro</i> and <i>in vivo</i> effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. <i>Oncotarget</i> , 2016, 7, 22531-22542.	1.8	23

#	ARTICLE	IF	CITATIONS
19	Pseudomonas Exotoxin A: optimized by evolution for effective killing. <i>Frontiers in Microbiology</i> , 2015, 6, 963.	3.5	181
20	Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. <i>Cancer Letters</i> , 2015, 367, 12-17.	7.2	109
21	Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer. <i>Oncotarget</i> , 2014, 5, 8681-8689.	1.8	39
22	Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. <i>Prostate</i> , 2014, 74, 743-755.	2.3	17
23	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. <i>Nature Medicine</i> , 2014, 20, 648-654.	30.7	241
24	Anti-PSMA Antibody-Drug Conjugates and Immunotoxins. , 2013, , 255-272.		0
25	Activation of RhoA,B,C by Yersinia Cytotoxic Necrotizing Factor (CNFy) Induces Apoptosis in LNCaP Prostate Cancer Cells. <i>Toxins</i> , 2013, 5, 2241-2257.	3.4	16
26	Antitumor activities of PSMA-CD3 diabodies by redirected T-cell lysis of prostate cancer cells. <i>Immunotherapy</i> , 2013, 5, 27-38.	2.0	23
27	Prostate Cancer-Targeted (2-Hydroxypropyl)methacrylamide Copolymer/Docetaxel Conjugates. <i>Macromolecular Bioscience</i> , 2012, 12, 412-422.	4.1	11
28	Effective targeting of prostate cancer by lymphocytes redirected by a PSMA-CD3 bispecific single-chain diabody. <i>Prostate</i> , 2011, 71, 588-596.	2.3	34
29	In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. <i>In Vivo</i> , 2011, 25, 55-9.	1.3	16
30	Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate Cancer. <i>Journal of Immunotherapy</i> , 2010, 33, 262-271.	2.4	36
31	Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. <i>Prostate</i> , 2010, 70, 562-569.	2.3	70
32	High-resolution animal PET imaging of prostate cancer xenografts with three different Cu ⁶⁴ -labeled antibodies against native cell-adherent PSMA. <i>Prostate</i> , 2010, 70, 1413-1421.	2.3	48
33	Primary prostate cancer cultures are models for androgen-independent transit amplifying cells. <i>Oncology Reports</i> , 2010, 23, 465-70.	2.6	12
34	Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. <i>Anticancer Research</i> , 2010, 30, 3373-9.	1.1	16
35	PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen. <i>Journal of Nuclear Medicine</i> , 2009, 50, 606-611.	5.0	92
36	Biorecognition and Subcellular Trafficking of HPMA Copolymer-anti-PSMA Antibody Conjugates by Prostate Cancer Cells. <i>Molecular Pharmaceutics</i> , 2009, 6, 959-970.	4.6	68

#	ARTICLE	IF	CITATIONS
37	Pseudomonas exotoxin A: From virulence factor to anti-cancer agent. International Journal of Medical Microbiology, 2009, 299, 161-176.	3.6	139
38	Targeting the prostate-specific membrane antigen for prostate cancer therapy. Immunotherapy, 2009, 1, 471-481.	2.0	17
39	Target-dependent T-cell Activation by Coligation With a PSMA α —CD3 Diabody Induces Lysis of Prostate Cancer Cells. Journal of Immunotherapy, 2009, 32, 565-573.	2.4	36
40	Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate, 2008, 68, 129-138.	2.3	23
41	A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate, 2006, 66, 1359-1370.	2.3	68
42	Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies. Frontiers in Oncology, 0, 12, .	2.8	9